Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

ZYCUBO ® has been given the green light by the FDA for treating Menkes disease in the US. Additionally, Cyprium Therapeutics, a Fortress subsidiary, finalized the transaction of its Rare Pediatric Disease Priority Review Voucher (PRV) for a whopping $205 million.